The grades of three Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Endocyte (NASDAQ:ECYT) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. In Portfolio Grader’s specific subcategory of Earnings Momentum, ECYT also gets an A. Shares of ECYT have increased 12.4% over the past month, better than the 4.2% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ECYT stock.
This week, Watson Pharmaceuticals (NYSE:WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Forest Laboratories (NYSE:FRX) earns a B this week, jumping up from last week’s grade of C. Forest Laboratories develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 6.7% over the past month. For more information, get Portfolio Grader’s complete analysis of FRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.